- Ipsen to buy blood cancer company Kartos Therapeutics for $450M upfrontIpsen is earmarking up to $1.75 billion to take Kartos Therapeutics and its MDM2 protein-targeting drug candidate that it in-licensed from Amgen back in 2016. Ipsen will pay $450 million upfront ...Endpoints · 28d ago↗ source
- De-Risking a Rare Disease Launch Starts with PrecisionWhy traditional models fall short in rare disease commercialization—and what works instead.Fierce Biotech · 1mo ago↗ source
- Biopharma’s LGBTQ+ leaders; Novo Nordisk hacked?; and moreWelcome back to another edition of Endpoints Weekly! The summer solstice arrives this weekend — the northern hemisphere will reach its maximum tilt toward the sun at 4:24 a.m. Eastern time on Sunda…Endpoints · 1mo ago